deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT05579730

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Evaluation of Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model

Sponsor: Bausch & Lomb Incorporated

Conditions Allergic Conjunctivitis
Interventions Brimonidine Tartrate 0.025% Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% Ketotifen Fumarate 0.035% Vehicle
Updated 8 times since 2022 Last updated: Jan 30, 2025 Started: Oct 12, 2022 Primary completion: Jul 22, 2023 Completion: Jul 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Allergic Conjunctivitis and is currently completed. Bausch & Lomb Incorporated leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshotNot Yet Recruiting~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshotNot Yet Recruiting~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshotRecruiting~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshotRecruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshotCompleted~Mar 2025 – present · 16 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  5. Jun 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

▶ Show 3 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  2. Dec 2022 — Mar 2023 [monthly]

    Not Yet Recruiting PHASE3

  3. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bausch & Lomb Incorporated
Data source: Bausch & Lomb Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations